Top Markets
#1 Velas Velas +367.73%
#2 Gravity Gravity +49.99%
#3 Galxe Galxe +35.17%
#4 Derive Derive +31.29%
#5 Infinity Ground Infinity Ground +29.18%
#6 Wiki Cat Wiki Cat +25.33%
#7 Audiera Audiera +24.94%
#8 Fuzzybear Fuzzybear +22.68%
#9 Fetch.ai Fetch.ai +22.26%
#10 Wrapped QUIL Wrapped QUIL +21.56%
Coin of the day
Velas Velas
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Peringkat dalam Saham #20716
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel... MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
Harga Saham
$0.00001
Kapitalisasi Pasar
$50.01K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan MultiCell Technologies, Inc. (MCET)

Kategori

Healthcare
Kapitalisasi Pasar
Pendapatan
lebih banyak
Keuntungan
Riwayat Harga
Rasio P/E
Rasio P/S
Rasio P/B
Margin Operasi
EPS
Pemecahan Saham
Dividen
Hasil Dividen
Saham Beredar
Margin Operasi untuk MultiCell Technologies, Inc. (MCET)
Margin Operasi per March 2026 TTM: -1,465.60%
Menurut laporan keuangan dan harga saham terbaru dari MultiCell Technologies, Inc., margin operasi saat ini (TTM) adalah -1,465.60%. Pada akhir 2013, margin operasi perusahaan adalah -2,773.89%.
Riwayat margin operasi untuk MultiCell Technologies, Inc. dari 2013 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Mengubah
2026 (TTM) -1,465.60% 0.00%
2014 -1,465.60% -47.16%
2013 -2,773.89% 0.00%
Margin Operasi untuk perusahaan sejenis atau pesaing
Perusahaan Margin Operasi Perbedaan Margin Operasi Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
41.30% -100.03%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
35.45% -100.02%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
24.95% -100.02%
US
UCB SA UCB SA
UCB SA
UCB.BR
25.32% -100.02%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.02%
AU
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.